Science and Technology › Biotechnology
Bioeconomy, biomanufacturing and biosafety
The bioeconomy and its safeguards: biomanufacturing and synthetic biology, the policies and bodies that fund them, biosafety laboratories and the rules on dual use research. It serves GS3 answers on biotechnology.
Showing 1 of 1 subject, those that changed from 16 to 31 July 2026.Show all
India's bioeconomy
Copy link to India's bioeconomyPrelims and Mains
India set out its vaccine and bioeconomy figures at a meeting in New Delhi. Volume, rather than value, is what the claim to be the world's largest producer rests on.
- The bioeconomy was valued at 195.3 billion United States dollars (USD) for 2025, 18 per cent up on the previous year.
- India puts its share at about 60 per cent of global vaccine production, reaching more than 100 countries.
- It meets over 65 per cent of the World Health Organisation's (WHO) routine immunisation requirements.
What changed
13 Sep 2026
17 Jul 2026Update
- A NITI Aayog roadmap proposes a ₹50,000 crore BioEconomy Growth Fund for 2026 to 35 and six national missions, including GeneIndia for gene and cell therapies and AgriBio 2.0 for gene edited crops, to take the bioeconomy to about $691 billion by 2035.
- Under the BioE3 policy of 2024, 17 biofoundries and biomanufacturing facilities have been funded, and a strain resource centre supplies indigenous production microbes.
The Hindu, 17 Jul 2026: NITI Aayog suggests ₹50,000-crore fund for biotech growth (opens in a new tab) · PIB, 16 Jul 2026: Government Focuses on Building Sovereign Biotechnology Ecosystem Through Talent, Innovation and Industry Partnerships: Dr Jitendra Singh (opens in a new tab) · PIB, 23 Jul 2026: PARLIAMENT QUESTION: IMPLEMENTATION OF BIOE3 POLICY (opens in a new tab)